Colorectal Cancer – Current Treatment – Current Treatment: Physician Insights – Colorectal Cancer (US)
Chemotherapy is the backbone of treatment for colorectal cancer, but treatment in the metastatic setting has expanded with the approval of several targeted agents. Well-established targeted approaches, including angiogenesis inhibitors (bevacizumab [Roche / Genentech], Zaltrap [Sanofi], and Cyramza [Eli Lilly]), EGFR inhibitors (Erbitux [Eli Lilly / Merck KGaA] and Vectibix [Amgen / Takeda]), and PD-1 inhibitors (Keytruda [Merck & Co.] and Opdivo ± Yervoy [Bristol Myers Squibb]), have rapidly expanded the treatment paradigm and improved disease outcomes. Furthermore, the FDA’s approval of HER2-targeted Tukysa (Seagen) in January 2023 and Fruzaqla (Hutchmed / Takeda) in November 2023 heralds the entry of more treatment options in this biomarker-defined patient population.
QUESTIONS ANSWERED
- What is the uptake of Keytruda in previously untreated / treated and of Opdivo ± Yervoy in previously treated metastatic MSI-H/dMMR colorectal cancer patients in the United States, according to surveyed medical oncologists?
- What is the patient share of key therapies used to treat RAS and BRAF wild-type and RAS– and BRAF-mutant metastatic colorectal cancer?
- What drivers and obstacles influence treatment decisions in the metastatic setting for select targeted therapies?
- How do drug-treatment rates vary between key colorectal cancer patient segments, according to biomarker status and line of therapy?
PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 100 medical oncologists in the United States fielded in April 2024.
Key drugs: Bevacizumab, Braftovi, Cyramza, Erbitux, Fruzaqla, Keytruda, Lonsurf, Opdivo, Stivarga, Tukysa, Vectibix, Yervoy, Zaltrap.
